Vanguard Global Advisers
IMVT icon

Vanguard Global Advisers’s Immunovant IMVT Stock Holding History

Vanguard Global Advisers’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.43M Buy
37,200
+3,577
+11% +$109K ﹤0.01% 1508
2026
Q1 		$835K Buy
+33,623
New +$870K ﹤0.01% 1755

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Global Advisers's IMVT Position: Q2 2026 in Review

Vanguard Global Advisers increased its Immunovant (IMVT) stake by 11% in Q2 2026, buying an estimated $109K and bringing the position to 37,200 shares worth $1.43M. The position accounts for ﹤0.01% of the portfolio, ranked #1508.

Vanguard Global Advisers first reported a position in IMVT in Q1 2026 and has held it in 2 quarters since. 224 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Vanguard Global Advisers held 37,200 shares of Immunovant worth $1.43M as of Q2 2026.
  • Vanguard Global Advisers bought 3,577 Immunovant shares in Q2 2026, an estimated $109K.
  • Immunovant made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1508 holding.
  • Vanguard Global Advisers first reported a position in Immunovant in Q1 2026 and has held it in 2 quarters since.
  • 224 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.